Gastric and Gastroesophageal Cancer
Gastric and gastroesophageal cancers exhibit diverse molecular drivers including HER2 alterations and genomic instability, influencing eligibility for targeted therapies.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Gastric and Gastroesophageal Cancer in FDA labeling.
Defined at the solid tumor level and applicable to Gastric and Gastroesophageal Cancer and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Gastric and Gastroesophageal Cancer. Select a therapy to view the specific approval and eligible tests.
ERBB2 (HER2) (gene amplification); ERBB2 (HER2) (HER-2 protein overexpression)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)